Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors

X
Trial Profile

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LCAR-C18S (Primary)
  • Indications Gastric cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Aug 2023 Status changed from recruiting to discontinued.
    • 17 Jun 2022 The inclusion criteria have been modified to include patients with solid tumors (including advanced gastric cancers and non-gastric cancers) and have failed to prior lines of systemic treatment. And the maximum age limit has been changed from 75 to 70 years, according to ClinicalTrials.gov record. Accordingly, the number of planned patients have been changed from 34 to 64.
    • 17 Jun 2022 Planned number of patients changed from 34 to 64.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top